In terms of the therapeutic targeting of angiogenesis, the first approved anti-angiogenic drug, bevacizumab, a monoclonal antibody directed against VEGF [17], has thus far been the drug most used for targeting the VEGF pathway in pituitary tumors. This evidence concerns the gene VEGFA and pituitary tumor.